文献速递外周动脉疾病

VQI数据库中外周动脉疾病混合手术快速增加

Rapid increase in hybrid surgery for the treatment of peripheral artery disease in the Vascular Quality Initiative database.
PubMed 文献 · J Vasc Surg · 2020-02-14

基于VQI 2010-2017年数据,混合下肢血运重建从6.1%增至32%。倾向匹配后比较股腘段混合手术与旁路手术各425例,混合手术围术期心梗和肾脏并发症更低、住院更短、出院回家率更高,但1年步行改善率较低,总体生存和无截肢生存无差异。

要点

  • 混合下肢血运重建占比从2010年6.1%升至2017年32%。
  • 股腘段混合手术围术期心梗和肾脏并发症低于旁路手术。
  • 1年总体生存和无截肢生存两组无显著差异。

核心结论

  • 混合下肢血运重建在外周动脉疾病中应用增加,占VQI开放血运重建近三分之一。
  • 股腘段混合手术围术期结局优于旁路手术,但1年结局相当。
  • 高危患者因围术期优势可优先考虑混合股腘段血运重建。

研究设计与样本

  • 基于美国国家血管质量倡议(VQI)数据库2010至2017年数据的回顾性队列研究。
  • 分析所有因外周动脉疾病接受旁路或混合下肢血运重建的患者趋势。
  • 倾向匹配年龄、性别、种族、指征、行走状态、急诊状态、糖尿病、高血压、冠心病、慢阻肺和血液透析后比较股腘段混合手术与旁路手术。

主要发现

  • 混合下肢血运重建总体率从2010年6.1%增至2017年32%(P = .03)。
  • 混合手术更常用于间歇性跛行患者(47%),旁路手术更常用于组织缺损患者(38.5%;P = .019)。
  • 匹配后混合手术组心梗1.9% vs 旁路5.7%(P = .005),肾脏并发症2.1% vs 6.7%(P = .003)。
  • 混合手术组住院4.7天 vs 旁路6.1天(P = .001),出院回家率90.8% vs 81.4%(P < .001)。
  • 30天死亡率无显著差异(混合1.5% vs 旁路2.5%;P = .44)。

关键数值与推荐

  • 股腘段混合手术定义为股动脉内膜切除加股腘血管顺行腔内介入。
  • 旁路手术定义为股动脉内膜切除加股腘旁路。
  • 匹配队列各425例,来自混合手术456例和旁路手术2665例。

临床怎么用

  • 高危外周动脉疾病患者行股腘段血运重建时可优先选择混合手术以降低围术期风险。
  • 选择混合手术需权衡其1年步行改善率可能低于旁路手术。
  • 混合手术不增加30天死亡率,且可缩短住院并提高出院回家率。

局限性

  • 研究为回顾性数据库分析,可能存在选择偏倚和未测量混杂。
  • 仅纳入VQI数据库中的中心,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Advances in technology have increased the use of endovascular therapy for lower extremity revascularization (LER), but the impact on hybrid surgery has not been studied. This study aims to (1) investigate the contemporary national trends in frequency of hybrid LER and (2) compare the outcomes of open bypass (BYP) and hybrid surgery for isolated femoropopliteal revascularization. METHODS: Using the national Vascular Quality Initiative database from 2010 to 2017, all patients receiving bypass or hybrid LER for PAD were identified. A trend of all hybrid LER compared with open LER was obtained. Next, only patients who underwent hybrid or open isolated femoropopliteal LER were identified. Patients treated with hybrid surgery underwent femoral endarterectomy and antegrade endovascular intervention of the femoropopliteal vessels (HYB), whereas patients treated with BYP underwent femoral endarterectomy and femoropopliteal bypass. These two groups of patients were matched based on age, gender, race, indication, ambulatory status, emergency status, diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, and hemodialysis. Patient characteristics and the perioperative and 1-year outcomes of the two groups were compared. RESULTS: The overall rate of hybrid LER procedures increased from 6.1% in 2010 to 32% in 2017 (P = .03). Hybrid LER was significantly more commonly used in patients with claudication (47%) and BYP surgery was used in patients with tissue loss (38.5%; P = .019). There were 456 HYB and 2665 BYP for isolated femoropopliteal revascularization. After propensity matching, the cohort comprised 425 patients in each group. HYB was associated with lower rate of myocardial infarction (1.9% vs 5.7%; P = .005) and renal complications (2.1% vs 6.7%; P = .003), length of stay (4.7 vs 6.1 days; P = .001), and higher rate of discharge to home (90.8% vs 81.4%; P < .001) compared with BYP. There was no significant difference in 30-day mortality (HYB 1.5% vs BYP, 2.5%; P = .44). The 1-year outcomes comparison suggested that patients in the BYP group had a higher likelihood of improvement in ambulatory status compared with patients in HYB group (16.7% vs 7.7%; P = .044). However, Kaplan-Meier analysis showed no difference in overall survival (P = .13) or amputation-free survival (P = .057) between the two groups. There was no statistical difference in graft patency, limb loss, or secondary interventions. CONCLUSIONS: Hybrid LER for PAD has been increasingly used and accounts for up to one-third of open LER in the Vascular Quality Initiative. Hybrid femoropopliteal revascularization improves perioperative outcomes compared with femoropopliteal bypass. However, the 1-year outcomes between the two procedures are comparable, suggesting that hybrid femoropopliteal revascularization should be favored in high-risk patients because of its perioperative advantages.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Fereydooni A, Zhou B, Xu Y, et al. Rapid increase in hybrid surgery for the treatment of peripheral artery disease in the Vascular Quality Initiative database. J Vasc Surg. 2020. PMID: 32067877. doi:10.1016/j.jvs.2019.11.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。